{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:32:52Z","timestamp":1794619972198,"version":"4.9.1"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.blre.2020.100689","type":"journal-article","created":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T19:06:10Z","timestamp":1585681570000},"page":"100689","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Therapeutic strategies in low and high-risk MDS: What does the future have to offer?"],"prefix":"10.1016","volume":"45","author":[{"given":"Emilia","family":"Scalzulli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Pepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gioia","family":"Colafigli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2020.100689_bb0005","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1056\/NEJMra0902908","article-title":"Myelodysplastic syndromes","volume":"361","author":"Tefferi","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100689_bb0010","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100689_bb0015","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100689_bb0020","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1200\/JCO.2016.71.0806","article-title":"Clinical implications of genetic mutations in myelodysplastic syndrome","volume":"35","author":"Kennedy","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100689_bb0025","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1182\/blood-2017-03-776070","article-title":"SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells","volume":"130","author":"Mortera-Blanco","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100689_bb0030","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1038\/leu.2017.192","article-title":"A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes","volume":"31","author":"Platzbecker","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2020.100689_bb0035","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1038\/s41375-018-0118-9","article-title":"A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-\u03b1 in anemic patients with low-risk MDS","volume":"32","author":"Fenaux","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2020.100689_bb0040","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1634\/theoncologist.12-10-1264","article-title":"Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis","volume":"12","author":"Ross","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.blre.2020.100689_bb0045","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1182\/blood.V120.21.2814.2814","article-title":"Prognostic factors of response to erythropoiesis stimulating agents (ESA) treatment in non RBC transfusion dependent lower risk MDS. Preliminary results of a French and Italian study (on behalf of the GFM and FISM)","volume":"120","author":"Park","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100689_bb0050","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/17474086.2017.1297704","article-title":"Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends","volume":"10","author":"Stahl","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.blre.2020.100689_bb0055","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1038\/s41375-018-0029-9","article-title":"A decade of progress in myelodysplastic syndrome with chromosome 5q deletion","volume":"32","author":"List","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2020.100689_bb0060","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1002\/cncr.28298","article-title":"Lenalidomide performance in the real world: patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes","volume":"119","author":"Zeidan","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2020.100689_bb0065","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.2010.31.8576","article-title":"TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression","volume":"29","author":"J\u00e4dersten","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100689_bb0070","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1038\/leu.2016.111","article-title":"Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS)","volume":"30","author":"Mossner","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2020.100689_bb0075","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3324\/haematol.2016.152025","article-title":"Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations","volume":"102","author":"Scharenberg","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2020.100689_bb0080","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/leu.2015.304","article-title":"Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes","volume":"30","author":"Sallman","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2020.100689_bb0085","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1200\/JCO.2015.66.0118","article-title":"Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents","volume":"34","author":"Santini","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100689_bb0090","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/leu.2015.296","article-title":"Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion","volume":"30","author":"Toma","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2020.100689_bb0095","doi-asserted-by":"crossref","first-page":"918","DOI":"10.3324\/haematol.2015.140988","article-title":"Groupe francophone des My\u00e9lodysplasies (GFM). A randomized phase II trial of azacitidine +\/\u2212 epoetin-\u03b2 in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents","volume":"101","author":"Th\u00e9pot","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2020.100689_bb0100","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1182\/blood-2017-06-788497","article-title":"Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS\/MPN","volume":"130","author":"Jabbour","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100689_bb0105","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1634\/theoncologist.2017-0215","article-title":"Azacitidine in lower-risk myelodysplastic syndromes: a meta-analysis of data from prospective studies","volume":"23","author":"Komrokji","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.blre.2020.100689_bb0110","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12878-016-0049-5","volume":"16","author":"Garcia-Manero","year":"2016","journal-title":"BMC Hematol"},{"key":"10.1016\/j.blre.2020.100689_bb0115","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1053\/j.seminhematol.2012.07.004","article-title":"Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab","volume":"49","author":"Parikh","year":"2012","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2020.100689_bb0120","article-title":"Use of immunosppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis","author":"Stahl","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2020.100689_bb0125","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00277-018-3539-7","article-title":"Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes","volume":"98","author":"Zeidan","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2020.100689_bb0130","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1182\/blood-2018-99-111134","article-title":"Safety and efficacy, including event-free survival, of deferasirox versus placebo in iron-overloaded patients with low- and int-1-risk myelodysplastic syndromes (MDS): outcomes from the randomized, double-blind Telesto study","volume":"132","author":"Angelucci","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100689_bb0135","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nm.3512","article-title":"Transforming growth factor-\u03b2 superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis","volume":"20","author":"Suragani","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2020.100689_bb0140","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/s41375-019-0448-2","article-title":"Transforming growth factor (TGF)-\u03b2 pathway as a therapeutic target in lower risk myelodysplastic syndromes","volume":"33","author":"Bewersdorf","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2020.100689_bb0145","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S1470-2045(17)30615-0","article-title":"Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study","volume":"18","author":"Platzbecker","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2020.100689_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2018-99-110805","volume":"132","author":"Fenaux","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100689_bb0155","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1016\/S2352-3026(18)30002-4","article-title":"Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial","volume":"5","author":"Komrokji","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2020.100689_bb0160","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1042\/CS20171625","article-title":"Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury","volume":"132","author":"Yang","year":"2018","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.blre.2020.100689_bb0165","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","article-title":"Roxadustat for anemia in patients with kidney disease not receiving dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100689_bb0170","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3343\/alm.2017.37.3.195","article-title":"Dysregulation of telomere lengths and telomerase activity in myelodysplastic syndrome","volume":"37","author":"Park","year":"2017","journal-title":"Ann Lab Med"},{"key":"10.1016\/j.blre.2020.100689_bb0175","first-page":"S1557","article-title":"Imetelstat in RBC transfusion-dependent lower risk MDS relapsed\/refractory to erythropoiesis-stimulating agents (IMerge): updated efficacy and safety","volume":"214476","author":"Fenaux","year":"2018","journal-title":"EHA Library"},{"key":"10.1016\/j.blre.2020.100689_bb0180","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1158\/1078-0432.CCR-14-1765","article-title":"A phase I study of oral ARRY-614, a p38 MAPK\/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes","volume":"21","author":"Garcia-Manero","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2020.100689_bb0185","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1016\/S2352-3026(18)30016-4","article-title":"Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial","volume":"5","author":"Kantarjian","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2020.100689_bb0190","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3026(17)30012-1","article-title":"Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial","volume":"4","author":"Oliva","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2020.100689_bb0195","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/leu.2011.234","article-title":"Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial","volume":"26","author":"Platzbecker","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2020.100689_bb0200","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1182\/blood-2007-02-076307","volume":"110","author":"Chang","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100689_bb0205","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2004-01-0338","article-title":"A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome","volume":"104","author":"Cutler","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100689_bb0210","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1200\/JCO.2012.46.8652","article-title":"Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis","volume":"31","author":"Koreth","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100689_bb0215","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100689_bb0220","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.bbmt.2017.05.034","article-title":"Hematopoietic cell transplantation in myelodysplastic syndromes after treatment with hypomethylating agents","volume":"23","author":"Festuccia","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2020.100689_bb0225","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ajh.24930","article-title":"Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management","volume":"93","author":"Montalban-Bravo","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2020.100689_bb0230","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"International Vidaza high-risk MDS survival study group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2020.100689_bb0235","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41408-018-0081-8","article-title":"Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?","volume":"8","author":"Zeidan","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2020.100689_bb0240","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s00277-019-03724-9","article-title":"Identification of predictive factors for overall survival at baseline and during azacytidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice","volume":"98","author":"Scalzulli","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2020.100689_bb0245","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1182\/blood-2010-06-289280","article-title":"Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacytidine","volume":"117","author":"Itzykson","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100689_bb0250","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1200\/JCO.2010.30.9245","volume":"29","author":"L\u00fcbbert","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100689_bb0255","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/bjh.14305","article-title":"Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes","volume":"175","author":"Zeidan","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2020.100689_bb0260","doi-asserted-by":"crossref","first-page":"27882","DOI":"10.18632\/oncotarget.25328","article-title":"Efficacy of azacitidine is independent of molecular and clinical characteristics-an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature","volume":"9","author":"Kuendgen","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2020.100689_bb0265","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2011.35.8135","article-title":"Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure","volume":"29","author":"Pr\u00e9bet","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100689_bb0270","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S1470-2045(15)00038-8","article-title":"Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study","volume":"16","author":"Issa","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2020.100689_bb0275","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(17)30576-4","article-title":"Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1\/2 trial","volume":"18","author":"Kantarjian","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2020.100689_bb0280","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.3324\/haematol.2018.207118","article-title":"Groupe francophone des My\u00e9lodysplasies (GFM). A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure","volume":"104","author":"S\u00e9bert","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2020.100689_bb0285","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S2352-3026(19)30029-8","article-title":"Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1\/2 trial","volume":"6","author":"Garcia-Manero","year":"2019","journal-title":"Lancet Hematol"},{"key":"10.1016\/j.blre.2020.100689_bb0290","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2019-122980","article-title":"Pharmacokinetic exposure equivalence and preliminary efficacy and safety from a randomized cross over phase 3 study (ASCERTAIN study) of an oral hypomethylating agent ASTX727 (cedazuridine\/decitabine) compared to IV decitabine","volume":"132","author":"Garcia-Manero","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100689_bb0295","series-title":"Treatment of MDS Blood","first-page":"1096","volume":"133","author":"Platzbecker","year":"2019"},{"key":"10.1016\/j.blre.2020.100689_bb0300","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/cncr.30533","article-title":"Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes","volume":"123","author":"Garcia-Manero","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2020.100689_bb0305","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/bjh.13323","article-title":"Pevonedistat (MLN4924), a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study","volume":"169","author":"Swords","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2020.100689_bb0310","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100689_bb0315","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100689_bb0320","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajh.25000","article-title":"Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","volume":"93","author":"DiNardo","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2020.100689_bb0325","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1182\/blood-2019-124994","article-title":"A phase 1b study evaluating the safety and efficacy of venetoclax as monotherapy or in combination with azacytidine for the treatment of relapsed\/refractory myelodysplastic syndromes","volume":"132","author":"Zeidan","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100689_bb0330","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1182\/blood-2019-124437","article-title":"A phase 1b study evaluating the safety and efficacy of venetoclax in combination with azacytidine in treatment-na\u00efve patients with higher risk myelodysplastic syndrome","volume":"132","author":"Wei","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100689_bb0335","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1182\/blood-2018-99-111264","article-title":"Ivosidenib (AG-120) induced durable remissions and transfusion independence in patients with IDH1-mutant relapsed or refractory myelodysplastic syndrome: results from a phase 1 dose escalation and expansion study","volume":"132","author":"DiNardo","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100689_bb0340","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood.V128.22.343.343","article-title":"Enasidenib (AG-221), a potent oral inhibitor of mutant isocitrate dehydrogenase 2 (IDH2) enzyme, induces hematologic responses in patients with myelodysplastic syndromes (MDS)","volume":"128","author":"Stein","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100689_bb0345","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2020.100689_bb0350","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1182\/blood-2018-99-119990","article-title":"Phase 1B\/2 combination study of APR-246 and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)","volume":"132","author":"Sallman","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100689_bb0355","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1470-2045(16)00009-7","article-title":"ONTIME study investigators. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial","volume":"17","author":"Garcia-Manero","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2020.100689_bb0360","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2020.100689_bb0365","first-page":"132","article-title":"A phase II study of nivolumab or ipilimumab with or without azacitidine for patients with myelodysplastic syndrome (MDS)","author":"Garcia-Manero","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100689_bb0370","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1158\/1078-0432.CCR-17-3763","article-title":"A multi-center phase I trial of ipilumumab in patients with myelodysplastic syndromes following hypomethylating agent failure","volume":"24","author":"Zeidan","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2020.100689_bb0375","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1182\/blood-2019-122896","volume":"132","author":"Zeidan","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100689_bb0380","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1182\/blood-2018-99-115720","article-title":"Preliminary results from a phase II study of the combination of azacitidine and pembrolizumab in patients with higher-risk myelodysplastic syndrome","volume":"132","author":"Chien","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100689_bb0385","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood-2018-99-118577","article-title":"PD-l1 blockade with atezolizumab in higher-risk myelodysplastic syndrome: an initial safety and efficacy analysis","volume":"132","author":"Gerds","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100689_bb0390","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1182\/blood-2019-128178","article-title":"Phase 1b study of the anti-TIM3 antibody MBG453 in combination with decitabine in patients with high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)","volume":"134","author":"Borate","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100689_bb0395","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1182\/blood.V130.Suppl_1.637.637","article-title":"Preliminary results of a phase 1 study of flotetuzumab, a CD123 x CD3 bispecific dart\u00ae protein, in patients with relapsed\/refractory acute myeloid leukemia and myelodysplastic syndrome","volume":"130","author":"Uy","year":"2017","journal-title":"Blood"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X20300394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X20300394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:27:20Z","timestamp":1759436840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X20300394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":79,"alternative-id":["S0268960X20300394"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2020.100689","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic strategies in low and high-risk MDS: What does the future have to offer?","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2020.100689","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100689"}}